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MicroRNAs have added a new dimension to our understanding of tumorigenesis and associated processes like
epithelial-to-mesenchymal transition (EMT). Here, we show that miR-375 is elevated in epithelial-like breast cancer
cells, and ectopic miR-375 expression suppresses EMT in mesenchymal-like breast cancer cells. We identified
short stature homeobox 2 (SHOX2) as a miR-375 target, and miR-375–mediated suppression in EMT was reversed
by forced SHOX2 expression. Ectopic SHOX2 expression can induce EMT in epithelial-like breast cancer cells,
whereas SHOX2 knockdown diminishes EMT traits in mesenchymal-like breast cancer cells, demonstrating
SHOX2 as an EMT inducer. We show that SHOX2 acts as a transcription factor to upregulate transforming growth
factor β receptor I (TβR-I) expression, and TβR-I inhibitor LY364947 abolishes EMT elicited by ectopic SHOX2
expression, suggesting that transforming growth factor β signaling is essential for SHOX2-induced EMT.
Manipulating SHOX2 abundance in breast cancer cells impact in vitro invasion and in vivo dissemination. Analysis
of breast tumor microarray database revealed that high SHOX2 expression significantly correlates with poor
patient survival. Our study supports a critical role of SHOX2 in breast tumorigenicity.
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The metastatic spread of epithelial cancer cells from the primary
tumor to distant organs is enhanced with the gain of mesenchymal
characteristics and the loss of epithelial features, a phenomenon
known as the epithelial-to-mesenchymal transition (EMT) [1,2].
During EMT, epithelial cells lose their epithelial characteristics
marked by the down-regulation of E-cadherin while acquiring a
mesenchymal phenotype characterized by the up-regulation of
mesenchymal proteins such as vimentin and N-cadherin (or cadherinCopyright © 2014 Neoplasia Press, Inc. All rights reserved 1476-5586/14
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RNAs that can posttranscriptionally silence the expression of target
genes by base pairing mostly with their 3′-untranslated regions (3′-
UTRs) [3]. Recent studies have demonstrated that miRNAs are
involved in the processes of tumor progression and EMT-associated
metastasis. For example, miR-205 and members of miR-200 family
can suppress EMT by silencing the expression of ZEB1 and ZEB2
[4,5]. Using a panel of human breast cancer cell lines exhibiting
both epithelial- and mesenchymal-like phenotypes, we revealed that
miR-200c, miR-205, and miR-375 are the miRNAs most
consistently upregulated in epithelial-like cells [6]. Despite the
well-established role of miR-200c and miR-205 in EMT, whether
miR-375 and its associated gene targets are involved in EMT
process has not been answered. Nevertheless, a recent study showed
that re-expressing miR-375 in tamoxifen-resistant breast cancer
MCF7 cells induces epithelial-like properties resembling tamoxifen-
nonresistant MCF7 cells [7], raising a possibility that miR-375 may
play a role in EMT.
Short stature homeobox 2 (SHOX2) is a homolog to the short
stature homeobox gene SHOX in humans. SHOX2 is the only SHOX
gene present in mice, and ablation of SHOX2 causes embryonic
lethality at midgestation due to cardiac and vascular defects [8].
Studies of SHOX2 conditional knockout mice further show that
SHOX2 plays an indispensable role in the formation of the proximal
portion of the limb skeleton and synovial joints [9,10]. Several recent
studies reported that hypermethylation of the SHOX2 DNA locus
could be a candidate biomarker for lung cancer [11]. These findings
underscore the relevance of SHOX2 in tumorigenesis. A potential
role of SHOX2 in tumorigenesis is also supported by the observations
that its expression is associated with tumor recurrence in hepatocel-
lular carcinoma (HCC) [12]. We recently showed that the expression
of SHOX2 has an inverse correlation with miR-375 in breast cancer
cell lines and is higher in mesenchymal-like breast cancer cells whereas
lower in epithelial-like ones [6]. However, it is absolutely unknown
whether SHOX2 plays a role in EMT or any other specific role in
tumorigenic process.
The objective of this study is to determine the relationship of miR-
375 and SHOX2 during EMT in breast cancer cells. With the aid of
multiple breast cancer cell lines, we reconfirmed the inverse
relationship between miR-375 and SHOX2 and showed that miR-
375 silenced SHOX2 expression by directly targeting the 3′-UTR of
SHOX2 mRNA. To determine the role of miR-375 in EMT, we
found that enforced miR-375 expression induced the expression of E-
cadherin while diminishing the expression of vimentin and blocking
in vitro invasion of mesenchymal-like breast cancer cells. However,
miR-375–mediated events were completely reverted by ectopic
SHOX2 expression, suggesting that miR-375 is involved in EMT
by regulating SHOX2 expression. In fact, knockdown of SHOX2
caused mesenchymal-like breast cancer cells to display an epithelial-
like phenotype, whereas ectopic expression of SHOX2 in epithelial-
like breast cancer cells led to EMT induction. These results
consequently demonstrate SHOX2 as an EMT inducer in breast
cancer cells. In an attempt to elucidate the underlying mechanism of
SHOX2-inducedEMT,we showed that this observed SHOX2-mediated
event was dependent on transforming growth factor β (TGF β) signaling
on the basis of the fact that TGFβ receptor I (TβR-I) inhibitor
LY364947 reverted mesenchymal-like phenotype of SHOX2-over-
expressing MCF7 and T47D cells back to their original epithelial-like
phenotype. SHOX2 directly impacts TGFβ signaling by acting as aTβR-I–specific transcription factor. By analyzing publicly available
microarray databases, we revealed that SHOX2 expression correlated
with both poor overall and recurrence-free survival of patients with
breast cancer. Moreover, we showed that depletion of SHOX2
blocked the ability of mesenchymal-like breast cancer cells to invade
in vitro and to disseminate in vivo, whereas ectopic SHOX2
expression converted epithelial-like breast cancer cells to be invasive
in vitro and disseminative in vivo. This study concludes that miR-
375/SHOX2 relationship is a potent EMT regulator and plays a
critical role in breast tumorigenicity.
Materials and Methods
Antibodies and Other Reagents
Detailed information on antibodies used for Western blot analysis,
immunofluorescence staining, and chromatin immunoprecipitation
(ChIP) were described in Supplementary Materials section. SHOX2
short hairpin RNA lentiviral constructs were purchased from Thermo
Fisher Scientific (RHS4430-101105065, RHS4430-101105700, and
RMM4431-99202942; Waltham, MA). LY364947 was obtained
from the LC Laboratories (Woburn, MA).
Cell Migration and In Vitro Invasion
Cell migration and in vitro invasion were analyzed using Transwells
(Corning Life Sciences, Tewksbury, MA) and Matrigel invasion
chamber (Cell Biolabs, San Diego, CA), respectively, as previously
described [13]. For cell migration, the undersurface of the upper
chamber of the Transwell was coated with 10 μg/ml collagen I
overnight at 4°C. Cells (1 × 105 cells per Transwell) were added into
the upper chamber and allowed 4 hours for cell migration. For in
vitro invasion, 2 × 105 cells were added into each upper chamber and
allowed 24 hours for invasion. After the period of migration or
invasion, cells on the undersurface of the upper units were stained and
counted under a phase-contrast microscope.
Quantitative Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from cells using TRIzol (Life
Technologies, Carlsbad, CA) and used to measure the amount of
SHOX2, E-cadherin, vimentin, TβR-I, TβR-II, TβR-III, and β-actin
mRNA. The amount of mature miR-375 was analyzed using miR-
375 TaqMan MicroRNA Assay kit (Life Technologies). The amount
of β-actin mRNA was used as the internal standardization.
Luciferase Reporter Gene Constructs and Luciferase Assay
SHOX2 3′-UTR luciferase reporter gene plasmid was constructed
by inserting the entire human SHOX2 3′-UTR sequence into the
pMiR vector (Life Technologies). TβR-I promoter luciferase reporter
gene plasmid was constructed by inserting 1504 bp of human TβR-I
promoter sequence into the pGL2 vector (Promega, Madison, WI).
To generate miR-375 targeting SHOX2 3′-UTR mutants and TβR-I
promoter mutated in Homeobox (HOX)-binding sites, site-directed
mutagenesis was performed on the respective wild-type plasmids
using QuikChange Site-Directed Mutagenesis Kit (Agilent Technol-
ogies, Santa Clara, CA). To determine luciferase activity, cells were
transfected with luciferase reporter gene plasmids for 2 days and then
lysed for measurement of luciferase activity. To normalize transfec-
tion efficiency, pGK-RLuc plasmid was included in all transfection
experiments and Renilla luciferase activity was used for standardiza-
tion. Luciferase activities were determined using Dual-Luciferase
Reporter Assay System (Promega).
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ChIP was performed as previously described [14,15]. Because there
is no SHOX2 antibody suitable for ChIP, MDA-MB-231 cells were
transfected with FLAG-tagged SHOX2 vector and subsequently
subjected to ChIP using anti-FLAG monoclonal antibody (mAb).
Cell Proliferation Assay
Cell proliferation was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay as previously described [16].
Cells were seeded in 24-well plates and cultured for 1 to 3 days following
with addition of MTT solution to the cells for 2 hours. After removing
the medium, the remaining MTT formazan crystals were solubilized in
DMSO and measured with a microplate reader at 560 nm.
Immunofluorescence Staining
Cells were cultured on coverslips overnight and fixed with 3%
paraformaldehyde, followed by the treatment of 1% Triton X-100
(Thermo Fisher,Waltham,MA) for permeabilization. To visualize the E-
cadherin and vimentin, we incubated the coverslips with the respective
antibodies for 1 hour and then rhodamine-conjugated secondary
antibody for another hour. The fluorescence staining was observed
with the aid of a fluorescence microscope (Axiovert 200M; Carl Zeiss,
Thornwood, NY). 4',6-diamidino-2-phenylindole (DAPI) was included
during staining to visualize nuclei of cells.
Zebrafish Tumor Cell Dissemination Model
The dissemination capability of cells was evaluated by a recently
established zebrafish metastasis model [17] and performed as
previously described [18]. All experimental procedures were approved
by the Experimental Animal Ethical Committee of Georgia Regents
University. Briefly, cells were first labeled with fluorescent dye CM-
Dil (Life Technologies), and approximately 200 labeled cells were
microinjected into the perivitelline space of 48-hour postfertilization
zebrafish embryos using a pressure microinjector. After confirmation
of a visible cell mass at the injection site, the embryos were transferred
to a 34°C incubator for 30 hours. To define the precise localization of
metastatic cells within the zebrafish, living zebrafish embryos were
imaged under anesthetic by confocal microscopy. Z-stack images were
processed using ImageJ as previously described [19].
Statistical Analysis
Statistical analyses of in vitro invasion assays and luciferase
activities were performed by the Student’s t test using Microsoft
Excel software (Redmond, WA). For SHOX2 analysis with human
breast tumor microarray data sets (Gene Expression Omnibus,
GSE18229 and GSE7390, National Center for Biotechnology
Information, Bethesda, MD), the cutoff value of high- and low-
SHOX2 expression groups was based on the sample median value.
Association between SHOX2 expression and clinical features was
analyzed by the Pearson χ2 tests. The correlation between SHOX2
and TβR-I expression was determined by Pearson correlation
coefficient. In univariate survival analyses, the Kaplan-Meier method
and the log-rank test were used to compare recurrence-free (data sets
GSE7390 and GSE18229) and overall survival curves (data set
GSE18229) between high- and low-SHOX2 expression groups. In
multivariate survival analysis, the Cox proportional hazards regression
model was used to identify important factors on overall survival for
breast cancer (data set GSE18229). This was performed by starting
with an initial model in which only SHOX2 expression was
considered and then adding a clinical feature one at a time to themodel. By repeating this procedure, the final regression model with
important factors was identified by a likelihood ratio test. Both
positive and negative association between overall survival and each
factor were tested in the Cox proportional hazards regression models
(i.e., one-sided test). P b .05 was considered statistically significant.
Results
MiR-375 Inhibits SHOX2 Expression in Breast Cancer Cells
By analyzing the miRNA expression profile of a panel of
established human breast cancer cell lines on microarray, we were
previously able to identify miR-375 along with miR-200c and miR-
205 as the miRNAs whose expression is consistently elevated in
epithelial-like breast cancer cell lines. In the same study, microarray
analysis also revealed that SHOX2, which contains the putative miR-
375 targeting sites in its 3′-UTR of mRNA, is preferentially expressed
in mesenchymal-like breast cancer cell lines. To confirm this inverse
correlation between miR-375 and SHOX2 in breast cancer cells, we
performed quantitative reverse transcription–polymerase chain reac-
tion (qRT-PCR) to analyze their expression in nine breast cancer cell
lines consisting of both epithelial-like and mesenchymal-like
phenotypes. The amount of miR-375 was much lower in
mesenchymal-like lines (characterized by vimentin expression) than
epithelial-like lines (characterized by E-cadherin expression) (Figure 1,
A and C). In contrast, SHOX2 mRNA and protein were highly
expressed in mesenchymal-like lines but were either low or
undetectable in epithelial-like lines (Figure 1, B and C). To determine
the potential regulatory role of miR-375 on SHOX2, we lentivirally
introduced miR-375 into MDA-MB-231 and Hs-578T cells.
Western blot analysis of the transduced cells showed that ectopic
miR-375 expression led to dramatic reduction in SHOX2 expression
(Figure 1D). The effect of miR-375 appeared to be specific because its
inhibitory outcome on SHOX2 expression was abolished by treating
cells with miR-375 inhibitor (Figure 1D).
The presence of putative miR-375 targeting sites in the 3′-UTR of
SHOX2 mRNA prompted us to determine whether SHOX2 mRNA
is a direct target of miR-375. We inserted SHOX2′s 3′-UTR
sequence into the luciferase reporter plasmid pMiR and transfected
this plasmid into miR-375–expressing MDA-MB-231 and Hs578T
cells. The luciferase activity was more than 70% lower in miR-375–
expressing cells when compared to the control (empty pMiR plasmid)
(Figure 1, E and F), suggesting SHOX2 mRNA as a miR-375 target.
To ascertain whether miR-375 targets SHOX2 mRNA through its
predicted pairing sites (on the basis of TargetScan program,
Whitehead Institute, Cambridge, MA) [20,21], we performed G/
C→C/G and A/U→U/A mutations in one or both of these sites to
disrupt the potential miR-375/SHOX2 mRNA interaction
(Figure 1E). Transfection experiments with these constructs
demonstrated that mutation in either site abolished the ability of
miR-375 to reduce luciferase activity (Figure 1F). These results show
that both of the putative miR-375 target sites in the 3′-UTR of
SHOX2 mRNA are critical for miR-375–mediated reduction in
SHOX2 expression in breast cancer cells.
miR-375/SHOX2 Interaction Regulates EMT in Breast
Cancer Cells
The low abundance of miR-375 in mesenchymal-like breast cancer
cells indicates that miR-375 could be a potential negative EMT
regulator (Figure 1A). To test this possibility, we examined several
EMT markers in MDA-MB-231 and Hs578T cells with ectopic
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diminished vimentin expression while inducing E-cadherin expres-
sion (Figure 2A). Matrigel invasion assay further showed that miR-
375 inhibited more than 70% of the in vitro invasion in both lines
(Figure 2B). The effect of miR-375 was clearly specific because
miR-375 inhibitor (anti–miR-375) abolished miR-375–induced
events (Figure 2B). To determine whether SHOX2 expression isfunctionally linked to miR-375, we enforced SHOX2 expression
in MDA-MB-231 and Hs578T cells with ectopic miR-375
expression. Forced SHOX2 expression restored vimentin expression
and cell migration and suppressed E-cadherin expression in these
miR-375–expressing cells (Figure 2, A and B). These results suggest
that miR-375 suppresses EMT by blocking SHOX2 expression in
breast cancer cells.
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lentivirally introducing SHOX2 shRNA into mesenchymal-like
MDA-MB-231 and Hs578T cells. Knockdown of SHOX2 decreased
the amount of both vimentin mRNA and protein while increasing the
level of E-cadherin mRNA and protein (Figure 2, C and D). SHOX2knockdown cells also displayed an epithelial morphology (Figure 2E)
and impaired cell migratory capability (Figure 2F). In a parallel study,
we lentivirally introduced SHOX2 into epithelial-like MCF7 and
T47D cells. Ectopically expressing SHOX2 diminished E-cadherin
expression and induced vimentin expression in both lines (Figure 3,
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microscopic observation, MCF7 and T47D cells with ectopic
SHOX2 expression displayed a mesenchymal morphology, whereas
control cells exhibited a typical epithelial cell phenotype (Figure 3C).
Moreover, ectopic SHOX2 expression also enhanced the migratory
capability of both MCF7 and T47D cells (Figure 3D) and triggered
significant expression of mesenchymal-specific Slug, Twist, ZEB1,
and ZEB2 (Figure W2). These results suggest that SHOX2 is a potent
inducer of EMT in breast cancer cells.
SHOX2 Regulates TβR-I Expression in Breast Cancer Cells
TGFβ signaling network plays an essential role in EMT of breast
cancer cells. To determine whether SHOX2 regulation of EMT is
functionally associated with the TGFβ signaling pathway, we
overexpressed SHOX2 in MCF7 and T47D cells and then treated
them with TβR-I inhibitor LY364947 or DMSO as vehicle. The
morphology of both control lines treated with or without LY364947
remained unchanged (Figure 4A). In contrast, the mesenchymal-like
morphology of SHOX2-overexpressing MCF7 and T47D cells was
reverted back to epithelial-like on treatment with LY364947
(Figure 4A). Western blot analysis further showed that LY364947
treatment restored E-cadherin expression and abolished vimentin
expression in SHOX2-overexpressing MCF7 and T47D cells
(Figure 4B). qRT-PCR also revealed identical results at the mRNA
level (Figure W3). These data suggest that SHOX2-induced EMT
depends on the TGFβ signaling network.To identify the TGFβ signaling network component that is
important for SHOX2-mediated EMT, we analyzed the mRNA levels
of TGFβ1, TGFβ2, TGFβ3, TβR-I, TβR-II, and TβR-III in MCF7
and T47D cells with ectopic SHOX2 expression. qRT-PCR showed
similar levels of TGFβ1, TGFβ2, and TGFβ3 mRNA between
control cells and cells with ectopic SHOX2 expression (Figure W4).
Among the TβRs, the amount of TβR-I increased more than five-fold
in MCF7 and eight-fold in T47D cells on ectopic SHOX2
expression, though little change was detected in TβR-II or TβR-III
(Figure 4, C and D). In a subsequent experiment, we examined the
abundance of TβRs in control and SHOX2 knockdown MDA-MB-
231 and Hs578T cells. Knockdown of SHOX2 diminished the
expression of TβR-I but not that of TβR-II and TβR-III mRNA and
protein (Figure 4, E and F). Pearson correlation coefficient analysis
with publicly available microarray data sets of human breast cancer
tissues also indicated a strong positive correlation between SHOX2
and TβR-I expression (ρ = 0.374; P b .001). These results clearly
show that SHOX2 regulates TβR-I expression in breast cancer cells.SHOX2 Activates TβR-I Promoter through the Consensus
HOX-Binding Site in TβR-I Promoter
To understand how modulating the abundance of SHOX2 alters
the level of TβR-I mRNA in breast cancer cells (Figure 4, C and
E), we determined the effect of SHOX2 knockdown on TβR-I
promoter activity in mesenchymal-like MDA-MB-231 and
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Figure 5. SHOX2 transcriptionally regulates TβR-I expression. (A) Effect of SHOX2 knockdown on TβR-I promoter activity in MDA-MB-231
and Hs578T cells. Data are means ± SEM (n = 3). #P b .01 versus shControl. (B) Effect of ectopic SHOX2 expression on TβR-I promoter
activity in MCF7 and T47D cells. Data are means ± SEM (n= 3). #P b .01 versus Control. (C) Effect of mutation in putative SHOX2-binding
site on TβR-I promoter activity in MDA-MB-231 and Hs578T cells or SHOX2-induced TβR-I promoter activity in MCF7 and T47D cells. Data
are means ± SEM (n= 3). #P b .01 versuswild-type (WT) or SHOX2 (−). (D) FLAG-SHOX2-transduced MDA-MB-231 cells were subjected
to ChIP with FLAG mAb or mouse IgG. Quantitative PCR (qPCR) was performed using a primer set that amplifies various regions in TβR-I
promoter. Data are means ± SEM (n = 3). *P b .05 versus Control (mouse IgG).
286 SHOX2/miR-375 in EMT Hong et al. Neoplasia Vol. 16, No. 4, 2014Hs578T cells. Luciferase activity assay showed that TβR-I
promoter activity was at least 75% lower when compared to
their respective control cells (Figure 5A). In parallel, we also
measured TβR-I promoter activity in epithelial-like MCF7 andT47D cells. Whereas TβR-I promoter activity was inherently low,
ectopic expression of SHOX2 induced a more than four-fold
increase in TβR-I activity (Figure 5B). These results show that
SHOX2 promotes TβR-I transcription in breast cancer cells.
Table 1. Correlation between SHOX2 Expression and Clinical Features (GSE7390 + GSE18229).
Clinical Features SHOX2 Expression* P Value**
Low (%) High (%)
Histologic grade
1 31 24 .339
2-3 186 198
Tumor diameter
b2 cm 87 75 .176
≥2 cm 137 157
Lymph node status
Negative 177 152 .001
Positive 47 84
ER receptor
Negative 71 103 .010
Positive 150 129
* Low/high by the sample median.
** Pearson χ2 test.
Neoplasia Vol. 16, No. 4, 2014 SHOX2/miR-375 in EMT Hong et al. 287Because SHOX2 contains the DNA-binding HOX domain, we
hypothesized that SHOX2 regulated TβR-I expression by acting as a
TβR-I–specific transcription factor in breast cancer cells. To test this
hypothesis, we analyzed the TβR-I promoter for HOX-binding
consensus sequence ATTA(N)nTAAT and identified two such sites
located at nucleotides −1238 to −1197 and −943 to −906 relative to
TβR-I transcription start site. We performed site-directed mutagen-
esis at nucleotides −1238 to −1237 and −943 to −942 in the TβR-I
promoter by switching ATTA to GCTA. Luciferase activity assay
showed that mutation at nucleotides −1238 to −1237, but not −943
to −942, abolished more than 70% of TβR-I promoter activity in
both MDA-MB-231 and Hs578T cells (Figure 5C). The mutagen-
esis at nucleotides −1238 to −1237 also incapacitated SHOX2 to
activate TβR-I promoter in MCF7 and T47D cells (Figure 5D),
suggesting that nucleotides −1238 to −1237 are the sites for
SHOX2 binding. In a parallel experiment, we performed ChIP
experiment in MDA-MB-231 cells transiently transfected with
FLAG-tagged SHOX2 using FLAG mAb or mouse IgG. PCR with
primers amplifying various regions of the TβR-I promoter showed
that there was an almost 12- and 18-fold greater amplification at the
regions spanning nucleotides −1341 to −1247 and −1223 to −
1110, respectively, (Figure 5E). Because HOX consensus sequence,
located at nucleotides −1238 to −1197, is within these two regions,
these results further support our finding that SHOX2 interacts
with TβR-I promoter through the HOX-binding site at nucleotides
−1238 to −1237.
SHOX2 Expression Correlates with Poor Survival of Patients
with Breast Cancer and Is Required for Breast Tumorigenicity
The ability of SHOX2 to regulate the EMT process indicates that
SHOX2 potentially plays a critical role in breast tumor progression.
To substantiate this claim, we first assessed the correlation between
SHOX2 expression and clinical features of patients with breast cancer
by analyzing two breast-tumor gene expression microarray data sets
available from Gene Expression Omnibus. In these data sets, high
SHOX2 expression correlated with positive lymph node status and
estrogen receptor (ER) negativity (P = .001 and .010, respectively;
Table 1). Because ER-negative breast tumors generally show less
differentiated (mesenchymal-like) phenotype, high expression of
SHOX2 in the ER-negative subtype of breast tumors is consistent
with its role as a facilitator of the EMT process.
Next, we evaluated the correlation between SHOX2 expression
and survival of patients with breast cancer. Univariate survival analysis
(Kaplan-Meier method and log-rank test) showed that low SHOX2
expression was associated with both high recurrence-free survival and
overall survival rates of patients (P = .041 for both sets; Figure 6, A
and B). Multivariate analysis (proportional hazards method) further
showed that SHOX2 expression was a bad prognostic factor along
with lymph node status and progesterone receptor (PGR) status
(Figure 6C).
To investigate the importance of SHOX2 in breast tumorigenicity,
we investigated how modulating SHOX2 expression affected cell
growth and in vitro invasion. Ectopic SHOX2 expression did not
affect cell growth in both MCF7 and T47D cells (Figure W5A).
However, knockdown of SHOX2 inhibited the growth rate of MDA-
MB-231 and Hs578T cells (Figure W5B), further suggesting its
importance in maintaining mesenchymal phenotype. However,
ectopic SHOX2 expression conferred MCF7 and T47D cells with
the ability to invade the Matrigel (Figure 6E), whereas knockdown ofSHOX2 led to a greater than 50% reduction in in vitro invasion in
both MDA-MB-231 and Hs578T cells (Figure 6D). In subsequent
experiments, a well-established zebrafish model was employed to
determine the effect of SHOX2 on breast cancer cell in vivo
dissemination. Fluorescence dye–labeled cells were microinjected into
the perivitelline space of 48-hour postfertilization zebrafish embryos.
Thirty hours after injection, dissemination of control MDA-MB-231
cells was seen in all zebrafishes (36 of 36), whereas SHOX2
knockdown MDA-MB-231 cells were only disseminated in 13.3% of
zebrafish (6 of 45) (Figure 6F). In contrast, control T47D cells were
not disseminated at all (Figure 6G); however, dissemination of T47D
cells with forced SHOX2 expression was observed in 88.9% of
zebrafishes (48 of 54) (Figure 6G). Together, these results strongly
suggest that SHOX2 plays a critical role in breast tumor cell
dissemination by facilitating the EMT process.
Discussion
Accumulating evidences have demonstrated a dynamic involvement
of the miRNA system in the process of EMT. In our previous
attempt to identify miRNAs specifically expressed in epithelial-like
breast cancer cells, we revealed that miR-200c, miR-205, and miR-
375 are most consistently expressed in epithelial-like breast cancer
cells [6]. The amount of miR-375 is elevated in ER-positive breast
cancer cells compared with ER-negative cells [22]. Analysis of
primary breast tumor tissues reveals that high miR-375 expression
is mainly detected in more differentiated tumors [23]. These
previous findings are in agreement with our observation that miR-
375 is specifically expressed in epithelial-like breast cancer cells that
are mostly ER positive (Figure 1). The ability of the miR-200
family and miR-205 to suppress EMT is well established [4,5]. As
one of the three miRNAs consistently expressed in epithelial-like
breast cancer cells, it is unknown whether miR-375 can also
suppress EMT. In this study, we show that ectopic miR-375
expression in mesenchymal-like breast cancer cells suppressed EMT
traits (Figure 2), demonstrating that, similar to well-characterized
miR-200c and miR-205, miR-375 is also an EMT-suppressive
miRNA. Low level of miR-375 expression is associated with poor
outcome and metastasis of head and neck squamous cell carcinoma
(HNSCC) [24]. Forced miR-375 expression can deter tumorige-
nicity of HNSCC [24] and HCC [25]. The tumor-suppressing role
of miR-375 in HNSCC and HCC is linked to its ability to target
astrocyte elevated gene-1 (AEG-1) [25,26]. However, we show that
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because forced SHOX2 expression is sufficient to restore EMT
traits blocked by miR-375 (Figure 2). Opposite to miR-375,
SHOX2 is preferentially expressed in mesenchymal-like breast
cancer cells (Figure 1). The inverse correlation between miR-375and SHOX2 expression is consistent with our finding that miR-
375 suppresses EMT by diminishing SHOX2 expression.
The involvement of SHOX2 in tumorigenesis has been
suggested since the discovery that hypermethylation of SHOX2
in bronchial aspirates and blood plasma is a clinically useful tumor
Neoplasia Vol. 16, No. 4, 2014 SHOX2/miR-375 in EMT Hong et al. 289marker for diagnosis of lung cancer [11,27]. Its expression is
recently shown to correlate with tumor recurrence in HCC [12]. In
this study, we demonstrate that depletion of SHOX2 is sufficient
to abrogate EMT traits in mesenchymal-like breast cancer cells
(Figure 2). Conversely, ectopic expression of SHOX2 in epithelial-
like breast cancer cells caused EMT (Figure 3), suggesting that
SHOX2 is an EMT inducer in breast cancer cells. Consistent with
its role in regulating EMT, SHOX2 expression is very low in
epithelial-like breast cancer cells (Figure 1). Knockdown of SHOX2
abolished both in vitro invasion and in vivo dissemination of
mesenchymal-like breast cancer cells, whereas forced SHOX2
expression confers epithelial-like breast cancer cells with the ability
to invade Matrigel and to disseminate in zebrafish (Figure 6).
Moreover, high expression of SHOX2 correlates with poor survival
of patients with breast cancer and hence is a poor prognostic factor
in patients with breast cancer. These data strongly suggest that
concurrent loss of miR-375 and gain of SHOX2 expression may be
an important step in breast tumor progression and metastasis.
SHOX2 contains the HOX domain and is thus likely to act as a
transcription factor. We show that SHOX2 directly facilitates TβR-I
expression by activating TβR-I gene transcription (Figure 5),
indicating that activation of TGFβ signaling network may be related
to SHOX2-induced EMT. This is clearly supported by the
observation that SHOX2-induced EMT in epithelial-like breast
cancer cells was reversed by the TβR-I inhibitor LY364947 (Figure 4).
TGFβ signaling is generally elevated in basal-like breast cancer cells
(they are generally mesenchymal-like), whereas it is poorly repre-
sented among luminal cells (they are generally epithelial-like) [28].
Our studies raise the possibility that SHOX2 is a critical molecule
linking mesenchymal-like breast cancer cells to their TGFβ signature.
Several other HOX domain–containing proteins, including Six1,
HOXB9, and Prrx1, have been shown capable of inducing EMT in
breast cancer cells [29-32]. Especially, both Six1 and HOXB9
facilitate EMT by activating TGFβ signaling [30,33]. We reason that
activation of TGFβ signaling may be a common pathway leading to
EMT of breast cancer cells.
Our study was performed with established breast cancer cell lines
that may not fully simulate clinical setting. However, the consistency
seen in the in vivo model and the excellent correlation between
SHOX2 expression and survival of patients with breast cancer in
breast tumors support the role of SHOX2 in breast tumorigenicity
established by our experimental studies. Our studies conclude that
miR-375/SHOX2 functional relationship regulates breast tumori-
genesis by controlling the process of EMT.References
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Antibodies
Antibodies used for Western blot analysis were all used at dilution of
1:1000. They include SHOX2 polyclonal antibody (kindly provided by
Dr Yi-Ping Chen at Tulane University, New Orleans, LA), Vimentin
mAb (Santa Cruz Biotechnology, Santa Cruz, CA, CatalogNo. sc-6260),
E-cadherin monolyclonal antibody (BD Biosciences, San Jose, CA,
Catalog No. 610405), β-Actin mAb (Santa Cruz Biotechnology, CatalogDAPI E
Control
SHOX2
DAPI
Control
SHOX2
A
B
Figure W1. Ectopic SHOX2 expression induces EMT characteristics i
MCF7 cells were subjected to immunofluoresence staining with E-caNo. sc-47778), TβR-I polyclonal antibody (Cell Signaling Technology,
Catalog No. 3712), TβR-II polyclonal antibody (Cell Signaling
Technology, Catalog No. 3713), and TβR-III polyclonal antibody
(Cell Signaling Technology, Danvers, MA, Catalog No. 2519).
Antibodies used for immunofluorescence staining were used at the
dilution of 1:200. They include E-cadherin monolyclonal antibody (BD
Biosciences, Catalog No. 610405) and Vimentin mAb (BD Biosciences,
Catalog No. 550513). FLAG mAb (Sigma, St. Louis, MO, Catalog No.
A2220) was used for ChIP (2 μg per reaction).-cadherin Merge
Vimentin Merge
n epithelial-like breast cancer cells. Control and SHOX2-expressing
dherin (A) or vimentin mAb (B). DAPI was used to visualize nuclei.
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Figure W2. Effect of ectopic SHOX2 expression on the expression of mesenchymal-specific transcription factors. qRT-PCR to determine
the levels of SLUG, SNAIL, TWIST, ZEB1, and ZEB2 mRNA in both control and SHOX2-overexpressing MCF7 (A) and T47D cells (B). Data
are means ± SEM (n = 3). *P b .01 versus Control.
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Figure W4. Effect of manipulating SHOX2 level on TGFβ1,TGFβ 2, and TGFβ3 mRNA. qRT-PCR was used to analyze the level of TGFβ1,
TGFβ2, and TGFβ3 mRNA in control and SHOX2 knockdown MDA-MB-231 (A), SHOX2 knockdown Hs578T (B), SHOX2-overexpressing
MCF7 (C), and SHOX2-overexpressing T47D cells (D). Data are means ± SEM (n = 3).
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